Rabih Darouiche, MD and Charles Love, MD to Present Live Webcast: ‘New Standards of Care for CRMD Antibiotic Protection’
MONMOUTH JUNCTION, N.J., Nov. 12 /PRNewswire/ -- TYRX, Inc., a leader in the development and commercialization of combination drug-device products, announced today that it has provided a grant for a complimentary live CME webcast hosted by leading physicians entitled, “New Standards of Care for CRMD Antibiotic Protection.” The Interactive Web Symposia will be presented live on November 18, 2008 at 6:00 p.m. EST and November 19, 2008 at 3:00 p.m. EST by Rabih O. Darouiche, MD and Charles J. Love, MD.
Dr. Darouiche, VA Distinguished Service Professor, Director, Center for Prostheses Infection, Baylor College of Medicine (Houston, TX), will present on the topic: “Prevention of Device-Related Infections.” Dr. Love, Professor of Clinical Medicine, Division of Cardiovascular Medicine, Ohio State University Medical Center and Director, Arrhythmia Device Services and Associate Investigator, Dorothy M. Davis Heart & Lung Research Institute (Columbus, OH), will present the topic: “Current Trends in Implantable Device Infection and Management.”
The program is designed to educate physicians, nurses and technologists to: address the pathogenesis of infections associated with pacemakers; and cardioverter defibrillators; assess the anti-infective efficacy of potentially preventive approaches; and describe the risks and costs associated with resolving device-related infections. Participants can register at the following web link: http://www.naccme.com/program/n-290/
“This CME program will provide participants with valuable information on a timely and important topic in the medical device and broader healthcare community,” said Bill Edelman, CEO of TYRX, Inc. “The CDC estimates that approximately one million hospital acquired infections each year are associated with indwelling devices and CMS has indicated that CRMD devices may be added to the no-pay list in 2010. This webcast will provide electrophysiologists and cardiac surgeons with valuable tools to help protect their patients, reduce implant infections and save unnecessary hospital costs. We are honored to provide a grant that enables Drs. Darouiche and Love, two of the most renowned experts in their fields, to address the topic of surgical site infection prevention.”
Participants will be provided with access instructions via email prior to the live presentation. A score of 70 percent or above will comprise a passing grade. A documentation of credit will be awarded to participants who successfully complete the exam. Those who successfully complete the post-test and evaluation form online may immediately print their documentation of credit. Physicians and nurses will be able to register online and complete the program for credit for one year following the webcast.
This activity is sponsored by the North American Center for Continuing Medical Education (NACCME). NACCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(TM).
NACCME is an approved provider of continuing nursing education by the Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. This continuing nursing education activity was approved by the PA State Nurses Association for 1 contact hour (Provider Number 110-3-E-06). Provider approved by the California Board of Registered Nursing, Provider Number 13255, for 1 contact hour.
About TYRX, Inc.
TYRX, Inc. is a global leader in the development of novel combination drug-device products that address surgical site infections (SSIs) across a broad range of surgical applications, including general, cardiovascular and cosmetic-surgical markets. TYRX’s lead product platform, AIGISRx CRMD (cardiac rhythm management device), is a 510k cleared antimicrobial surgical mesh designed to deliver site specific therapy to prevent SSIs following CRMD implantation. The combination medical products sector (products incorporating both a drug and a device component) is expected to be the highest growth segment of the medical products industry, and TYRX is positioned to be an innovative leader in this space.
TYRX, an IS0 9001:2000 and IS0 13485:2003 certified medical device manufacturer, has exclusively licensed product patents and associated technologies from Rutgers, The State University of New Jersey, Baylor College of Medicine and The University of Texas M.D. Anderson Cancer Center. More information may be found at www.TYRX.com.
CONTACT: Bill Edelman, President and CEO, TYRX, Inc., +1-732-246-8676,
william@TYRX.com; or Media, Jennifer Saunders, The Ruth Group,
+1-646-536-7011, jsaunders@theruthgroup.com
Web site: http://www.TYRX.com/
